CoreSite Realty

CoreSite Realty

Yahoo Finance • 16 days ago

Camino Receives Environmental Approval for Significant Exploration Expansion at the Costa de Cobre Copper Project in Peru

Approval Nearly Doubles Exploration Footprint and Adds 212,500 Metres of Potential Drilling CapacityAcross Three Major Copper Trends VANCOUVER, BC / ACCESS Newswire / September 28, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF... Full story

Yahoo Finance • 18 days ago

Cencora Elects Robert E. Sanchez to Its Board of Directors

CONSHOHOCKEN, Pa., September 25, 2026--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Execu... Full story

Yahoo Finance • 23 days ago

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Key Points Interested in Cencora, Inc.? Here are five stocks we like better. Specialty pharmaceuticals and MSOs are central to Cencora's growth strategy, with particular emphasis on retina and oncology practices. Management expects the MS... Full story

Yahoo Finance • 23 days ago

Notable healthcare headlines for the week: Novo Nordisk, GE HealthCare, and Eli Lilly in focus

Wall Street's major market averages finished mixed as Treasury yields rebounded, rekindling concerns about a deteriorating macroeconomic backdrop. The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#source=url_first_level%3Amarket-n... Full story

Yahoo Finance • 24 days ago

Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?

On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and mana... Full story

Yahoo Finance • 27 days ago

Cencora Tech Chief: AI Is Cutting Some Medical Treatment Decisions in Half

Cencora Global Chief Data and Information Officer Pawan Verma spoke with WSJ Leadership Institute President Alan Murray at the WSJLI Technology Council Summit about how AI is being used in healthcare to speed access to treatment. Verma des... Full story

Yahoo Finance • 29 days ago

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026? AbbVie is... Full story

Yahoo Finance • 29 days ago

Coultreon Biopharma Appoints Nate Massari as Chief Business Officer

Coultreon Biopharma BV Nate Massari's business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn's disease, will support the advancement of Coultreon's first-in-cl... Full story

Yahoo Finance • 29 days ago

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amge... Full story

Yahoo Finance • last month

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate d... Full story

Yahoo Finance • last month

2 S&P 500 Stocks with Exciting Potential and 1 We Question

2 S&P 500 Stocks with Exciting Potential and 1 We Question The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are c... Full story

Yahoo Finance • last month

Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

Should you bet on an established giant or a pipeline-driven innovator? This comparison examines Amgen (NASDAQ:AMGN) and Moderna (NASDAQ:MRNA) to see which stock is a better buy today. Amgen is a veteran in the drug manufacturing world, fo... Full story

Yahoo Finance • last month

Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen

Cencora COR raised its fiscal 2026 adjusted earnings outlook after third-quarter results showed faster profit growth across both healthcare solutions segments. Adjusted earnings per share rose 12% year over year to $4.48, topping the Zacks... Full story

Yahoo Finance • last month

Artisan Sold Cencora (COR) as Earnings Momentum Slowed

Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the "Artisan Global Opportunities Strategy". The letter can be downloaded here. Global equities rebounded sharply during the quart... Full story

Yahoo Finance • last month

Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs

New offering helps health systems strengthen financial confidence, operational readiness and program scalability to support broader patient access to cell and gene therapies CONSHOHOCKEN, Pa., September 02, 2026--(BUSINESS WIRE)--Cencora... Full story

Yahoo Finance • last month

Beat the Market the Zacks Way: Accelerant, Insight, General Mills in Focus

Last week, major U.S. indexes were driven by a tug-of-war between strong corporate earnings/AI optimism and renewed concerns about the Federal Reserve's policy. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained... Full story

Yahoo Finance • last month

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between AbbVie Inc (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) requires balancing the potential for aggressive pharmaceutical growth against the stability of a diversified medical conglomerate. AbbVie is a focused biopharmaceuti... Full story

Yahoo Finance • last month

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Axsome Therapeutics (NASDAQ:AXSM) means weighing the established stability of a global pharmaceutical leader against the rapid growth of an emerging central nervous system specialist. Amgen operate... Full story

Yahoo Finance • 2 months ago

Cardinal Health a new outperform at RBC on higher margin services

[Wall Street New York stock exchange stock market] alexsl * RBC Capital Markets initiated coverage of Cardinal Health (CAH [https://seekingalpha.com/symbol/CAH]) at outperform, saying that the drug wholesaler will benefit from "vertical... Full story

Yahoo Finance • 2 months ago

"Trumpflation" Is Real -- and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

The latest Consumer Price Index showed prices 3.4% higher in July than a year ago, well above the Federal Reserve's 2% target. Energy prices jumped 14.7%, electricity rose 4.2%, and food increased 3%. Producer prices, meanwhile, remained 4... Full story